Evaluating I-SPY2 Clinical Data & Toxicity Monitoring to Assess ADC Progression to Early-Stage Oncology Settings in TNBC & HER2+ Breast Cancer
- Contextualizing I-SPY2 trials evaluating progression of ADCs to neoadjuvant and adjuvant settings in TNBC & HER2+ breast cancer
- Laying out clinical data generated to investigate early-line ADC progression, including recent clinical performance of Enhertu and Datroway
- Evaluating concerns with ADC-associated side effects, focusing on ILD monitoring, when considering advancement to neoadjuvant settings